Matches in SemOpenAlex for { <https://semopenalex.org/work/W2546123715> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2546123715 endingPage "A535" @default.
- W2546123715 startingPage "A535" @default.
- W2546123715 abstract "Biologic drugs such as infliximab, etanercept, and adalimumab used in the treatment of rheumatoid arthritis (RA) represent a significant economic burden on healthcare systems. To understand this burden, we examined the economic evidence from Nordic countries surrounding these 3 treatments, and compared them from the healthcare system’s perspective. A structured review of published literature in English was conducted using Medline and Embase databases. We included economic and modeling studies that assessed implicit and explicit costs of select biologic treatments. Data were extracted for different cost items such as drug acquisition cost, monitoring and administration costs, and related healthcare utilization costs. Unit and itemized costs were calculated. To enable comparison across drugs, all costs were converted to 2015 Swedish Krona (SEK) using consumer price indices from OECD. Of the 210 references found in the literature search, 21 articles from Nordic countries (Sweden: 14; Norway: 5; Finland: 2) were included for analysis. Mean annual cost of RA treatment was calculated for patients treated with etanercept (SEK 169,322), adalimumab (SEK 174,415) and infliximab (SEK 137,359 to 188,507). Drug acquisition cost was the primary cost-driver across treatments and accounted for an average of 69% of the total cost. Due to intravenous administration, the cost of drug administration and monitoring was highest in infliximab. This cost item was 2.15%, 2.09%, and 7.52% of the total costs in etanercept, adalimumab, and infliximab respectively. Patients on infliximab also had more hospitalizations than those on etanercept or adalimumab, representing a higher healthcare utilization cost. There is paucity of recent data for indirect costs associated with RA. The presence of biosimilar infliximab has both increased competition in the RA market and widened the cost range for infliximab. The future introduction of additional biosimilars, and their associated costs, will invoke competition in the near future." @default.
- W2546123715 created "2016-11-04" @default.
- W2546123715 creator A5004135550 @default.
- W2546123715 creator A5034850163 @default.
- W2546123715 creator A5038170254 @default.
- W2546123715 creator A5047617586 @default.
- W2546123715 creator A5070401244 @default.
- W2546123715 creator A5085846525 @default.
- W2546123715 creator A5086415460 @default.
- W2546123715 creator A5088685899 @default.
- W2546123715 date "2016-11-01" @default.
- W2546123715 modified "2023-09-26" @default.
- W2546123715 title "Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated With Infliximab, Etanercept And Adalimumab In Nordic Setting" @default.
- W2546123715 doi "https://doi.org/10.1016/j.jval.2016.09.1096" @default.
- W2546123715 hasPublicationYear "2016" @default.
- W2546123715 type Work @default.
- W2546123715 sameAs 2546123715 @default.
- W2546123715 citedByCount "0" @default.
- W2546123715 crossrefType "journal-article" @default.
- W2546123715 hasAuthorship W2546123715A5004135550 @default.
- W2546123715 hasAuthorship W2546123715A5034850163 @default.
- W2546123715 hasAuthorship W2546123715A5038170254 @default.
- W2546123715 hasAuthorship W2546123715A5047617586 @default.
- W2546123715 hasAuthorship W2546123715A5070401244 @default.
- W2546123715 hasAuthorship W2546123715A5085846525 @default.
- W2546123715 hasAuthorship W2546123715A5086415460 @default.
- W2546123715 hasAuthorship W2546123715A5088685899 @default.
- W2546123715 hasBestOaLocation W25461237151 @default.
- W2546123715 hasConcept C121955636 @default.
- W2546123715 hasConcept C126322002 @default.
- W2546123715 hasConcept C144133560 @default.
- W2546123715 hasConcept C160735492 @default.
- W2546123715 hasConcept C162324750 @default.
- W2546123715 hasConcept C162853370 @default.
- W2546123715 hasConcept C177713679 @default.
- W2546123715 hasConcept C17991360 @default.
- W2546123715 hasConcept C1862650 @default.
- W2546123715 hasConcept C194828623 @default.
- W2546123715 hasConcept C2777138892 @default.
- W2546123715 hasConcept C2777226972 @default.
- W2546123715 hasConcept C2777575956 @default.
- W2546123715 hasConcept C2780132546 @default.
- W2546123715 hasConcept C50522688 @default.
- W2546123715 hasConcept C6964187 @default.
- W2546123715 hasConcept C71924100 @default.
- W2546123715 hasConcept C95821633 @default.
- W2546123715 hasConceptScore W2546123715C121955636 @default.
- W2546123715 hasConceptScore W2546123715C126322002 @default.
- W2546123715 hasConceptScore W2546123715C144133560 @default.
- W2546123715 hasConceptScore W2546123715C160735492 @default.
- W2546123715 hasConceptScore W2546123715C162324750 @default.
- W2546123715 hasConceptScore W2546123715C162853370 @default.
- W2546123715 hasConceptScore W2546123715C177713679 @default.
- W2546123715 hasConceptScore W2546123715C17991360 @default.
- W2546123715 hasConceptScore W2546123715C1862650 @default.
- W2546123715 hasConceptScore W2546123715C194828623 @default.
- W2546123715 hasConceptScore W2546123715C2777138892 @default.
- W2546123715 hasConceptScore W2546123715C2777226972 @default.
- W2546123715 hasConceptScore W2546123715C2777575956 @default.
- W2546123715 hasConceptScore W2546123715C2780132546 @default.
- W2546123715 hasConceptScore W2546123715C50522688 @default.
- W2546123715 hasConceptScore W2546123715C6964187 @default.
- W2546123715 hasConceptScore W2546123715C71924100 @default.
- W2546123715 hasConceptScore W2546123715C95821633 @default.
- W2546123715 hasIssue "7" @default.
- W2546123715 hasLocation W25461237151 @default.
- W2546123715 hasOpenAccess W2546123715 @default.
- W2546123715 hasPrimaryLocation W25461237151 @default.
- W2546123715 hasRelatedWork W1973470095 @default.
- W2546123715 hasRelatedWork W1975769455 @default.
- W2546123715 hasRelatedWork W1976481621 @default.
- W2546123715 hasRelatedWork W1993992685 @default.
- W2546123715 hasRelatedWork W2089375357 @default.
- W2546123715 hasRelatedWork W2162936925 @default.
- W2546123715 hasRelatedWork W2341567294 @default.
- W2546123715 hasRelatedWork W23797247 @default.
- W2546123715 hasRelatedWork W4200063390 @default.
- W2546123715 hasRelatedWork W94518001 @default.
- W2546123715 hasVolume "19" @default.
- W2546123715 isParatext "false" @default.
- W2546123715 isRetracted "false" @default.
- W2546123715 magId "2546123715" @default.
- W2546123715 workType "article" @default.